BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for BioXcel Therapeutics and Legend Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioXcel Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Legend Biotech | 1 | 6 | 8 | 0 | 2.47 |
BioXcel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 14,744.80%. Legend Biotech has a consensus price target of $53.43, indicating a potential upside of 168.35%. Given BioXcel Therapeutics’ higher possible upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Legend Biotech.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioXcel Therapeutics | $640,000.00 | 3.63 | -$69.90 million | ($3.79) | -0.02 |
| Legend Biotech | $1.03 billion | 3.75 | -$296.80 million | ($0.25) | -79.64 |
BioXcel Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioXcel Therapeutics and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioXcel Therapeutics | -9,549.87% | N/A | -185.82% |
| Legend Biotech | -7.21% | -8.71% | -5.40% |
Risk & Volatility
BioXcel Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Insider & Institutional Ownership
30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Legend Biotech beats BioXcel Therapeutics on 9 of the 14 factors compared between the two stocks.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
